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1. Introduction 
Renal disease is common throughout the world. In the United States alone, almost 100,000 
people began renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 
2001(Kimmel & Peterson, 2005); by 2008, this number had increased to 485,000 patients 
(Collins et al., 2009). More than 90% of these patients were started on hemodialysis (HD), 
while only 8.5% began RRT with peritoneal dialysis (PD)(Kimmel & Peterson, 2005). In 
Korea, the number of dialysis centers and machines has continuously increased, and 62.1% 
of patients receiving RRT were being treated with HD (Son et al., 2009). An international 
comparison showed that Taiwan has the greatest incidence and second-greatest prevalence 
of ESRD (Kuo et al., 2007). Furthermore, renal disease is one of the top 10 causes of death in 
Taiwan, and roughly 95% of ESRD patients are on HD (Hsieh et al., 2007). 
While HD does not cure renal disease, its use does allow patients with ESRD to survive 
(Weisbord et al., 2007a). Nevertheless, HD is a lifelong treatment that significantly and 
sometimes adversely affects patients both physically and mentally (Kimmel, 2001). Common 
psychological effects include depression, anxiety, fatigue, decreased quality of life (QoL) 
and increased suicide risk (Chen et al., 2010). The global effects of continual treatment lead 
to changes in patients’ family roles and ability to work, with feelings of loss of control and 
fear of death. These very real psychological consequences of treatment may affect survival 
in HD patients (Chilcot et al., 2011; Kimmel & Peterson, 2005). Therefore, it is imperative to 
identify and treat these psychological symptoms among HD patients. 
2. Depression  
2.1 Prevalence and influence of depression  
Depression is one of the most common psychological problems among HD patients. We still 
lack reliable data that can be used to directly compare the prevalence of depression between 
HD patients and the general population. However, extant investigations generally agree 
that the rate of depression is high among HD patients.  
In the general population, the lifetime prevalence of major depressive disorder is about 
16.2% (Kessler et al., 2003). However, the rates vary widely across countries, ranging from 
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Study 
Number of 
patients 
Assessment 
tools 
Prevalence Additional out
Kurella et al. 
(2005)  
465,563 
Medical 
evidence form 
in Medicare 
and Medicaid 
Services  
Withdrew from dialysis: 
9.6%  
Died from suicide: 
0.005%  
Persons with ESRD had 
significantly higher suicide rate
than in the general population
Independent predictors of
suicide: age >75 yr, male gen
geographic region, a
drug dependence, and
hospitalization with mental 
illness. 
Taskapan et al. 
(2005) 
40 
HDRS, HARS, 
PRIME-MD, 
MMSE, SF-36 
Depression: 30% 
Anxiety: 35%  
Somatoform disorder: 
32.5% 
All patients' MMSE were normal. 
No relationship between any 
psychiatric disorder 
demographic characteristics. 
Negative correlation 
weight gain and QoL during 
dialysis. 
Drayer et al. 
(2006)  
62 
PRIME-MD, 
KDQOL-SF 
Depression: 28% 
Depressed patients were younger 
and had lower health-related 
QoL. Depression predicted 
mortality in a mean duration of 
29 months. 
Kalender et al. 
(2007a)  
HD: 68 
PD: 47 
BDI, SF-36 
Depression in HD: 
33.8% 
Depression in PD: 12.8% 
Significant negative 
between QoL and depression. 
Significant positive correlat
between the QoL and the H
value and serum albumin lev
Inverse correlation between 
QoL and the serum CRP level 
the HD patients. 
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Study 
Number of 
patients 
Assessment 
tools 
Prevalence Additional out
Cukor et al. (2008)  70 
SCID, HADS, 
KDQOL-SF 
Depression: 29% 
Anxiety: 45.7% 
Patients with persistent
marked decreases
health status, compared with 
and intermittently depresse
Hedayati et al. (2008)  98 
SCID, BDI, CDI, 
CESD 
Depression: 26.7% 
Major depression: 17.3% 
There were no difference
hospitalization for 
depressed. Patients with 
increased risk of death 
year. 
Ibrahim & Salamony 
(2008)  
60 
BDI, SF-36, DSI, 
MIS 
Depression: 33.3% 
Depression was affected by employment and 
marital status. DSI and MIS 
correlations with BDI scores a
correlations with SF-36 scores
Hsu et al. (2009)  51 HADS Depression: 35% 
Depression was less co
used polysulfone dialyzers th
who used cellulose de
Depression was also a
albumin, and number of comorbidities.
Kao et al. (2009)  861 SF-36, BDI 
Depression: 60.5% 
Insomnia: 31.0% 
Fatigue: 30.6% 
Depression scores were negatively 
with QoL. Higher monthly income and 
increased social act
better health-related QoL. 
Son et al. (2009)  146 
BDI, PHQ-9, 
KDQOL 
Depression: 25.3% 
There were more symptoms a
reported in depressed patients than 
depressed ones.  
Bossola et al. (2010)  80 
BDI, HARS, SF-
36, SCL-90-R 
,CCI; MMSE 
Depression: 52.5%  
Mild anxiety: 47.5% 
Moderate to severe 
anxiety: 48.7% 
BDI score correlated 
CCI, SF-36 Vitality Subs
albumin, plasma 25-hydroxy vitamin D
6 levels. 
w
w
w
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KEY: BDI: Beck Depression Inventory; CCI: Charlson Comorbidity Index; CESD: Center of 
Epidemiological Studies Depression Scale; CFS: Chalder Fatigue Scale; CKD: chronic kidney disease; 
COPE: Coping Orientation to Problems Experienced Inventory; CRP: C-reactive protein; DSI: Dialysis 
Symptom Index; HADS: Hospital Anxiety and Depression Rating Scale; ESRD: end-stage renal disease; 
HARS: Hamilton Anxiety Rating Scale; HD: hemodialysis; HDRS: Hamilton Depression Rating Scale; 
IL: interleukin; KDQoL: Kidney Disease Quality of Life; KDQoL-SF: Kidney Disease and Quality of Life 
Short Form; MINI: Mini International Neuropsychiatric Interview; MIS: Malnutrition-Inflammation 
Score; MMSE: Mini Mental State Examination; PD: peritoneal dialysis; PHQ-9: Patient Health 
Questionnaire; PRIME-MD: Primary Care Evaluation of Mental Disorders; SBQ: Suicide Behaviours 
Questionnaire; SCID: Structured Clinical Interview for DSM; SCL-90-R: Hopkins Symptom Checklist 90 
Revised; SF-36: The Short-form Health-related Quality of Life; TNF: tumor necrosis factor 
Table 1. Psychological impacts in hemodialysis patients demonstrated in recent studies 
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The variation in prevalence rates of depression might be accounted for by differences in 
sample sizes and assessment tools (Watnick et al., 2005). Despite such discrepancies, 
depression is unquestionably one of the most important mental illnesses among HD 
patients. Strong correlations have been noted between depression and longitudinal outcome 
among HD patients, including poor treatment adherence and higher mortality rates (Drayer 
et al., 2006; Kimmel et al., 1993). In addition, depression in HD patients is associated with 
higher rates of hospital admission, and a greater likelihood of emergency department visits 
(Abbas Tavallaii et al., 2009; Hedayati et al., 2008).  
2.2 Biological factors underlying depression 
The etiology of dialysis-related depression is multifactorial, and is related to biological, 
psychological, and social mechanisms (Chilcot et al., 2008). Some of the biological 
mechanisms include increased cytokine levels, possible genetic predisposition, and 
neurotransmitters affected by uremia (Kimmel, 2001; Smogorzewski et al., 1995).  
For decades it’s been known that immunologic factors have potent influences on 
neurotransmitter metabolism and neuroendocrine function (Irwin & Miller, 2007; Wichers & 
Maes, 2002). A growing number of studies have investigated the relationships between 
cytokines and depression (Howren et al., 2009; Loftis et al., 2010; Sonikian et al., 2010). 
During hemodialysis, the blood-dialyzer interaction has the potential to activate 
mononuclear and dendritic cells, leading to production of inflammatory cytokines (Agrawal 
et al., 2010; Pertosa et al., 2000). Several researchers support the supposition that pro-
inflammatory cytokines are involved with depression in renal patients. In particular, there is 
evidence that depression is associated with interleukin (IL)-1, IL-6, tumor necrosis factor-
alpha (TNF-α), and C-reactive protein (CRP) in both the general and ESRD populations (Gill 
et al., 2010; Simic Ogrizovic et al., 2009; Sonikian et al., 2010). These pro-inflammatory 
cytokines also appear to be associated with survival rate in HD patients (Kimmel et al., 
1998). The underlying biological mechanisms have been proposed as a defect in serotonergic 
function and hypercortisolemia associated with stimulation of the hypothalamic-pituitary-
adrenal (HPA) axis (Capuron & Miller, 2011; Leonard, 2010), thus leading to depression and 
affecting mortality.  
Malnutrition, which is commonly observed in dialysis patients, is related to chronic 
inflammation (Pertosa et al., 2000). It has also been reported that malnutrition is associated 
with emotional symptoms among HD patients (Bossola et al., 2009; Czira et al., 2011; Huang 
& Lee, 2007; Ibrahim & El Salamony, 2008; Koo et al., 2003). These authors also determined 
that patients with depression had lower-than-normal body mass indices (BMI) (Chen et al., 
2010).  
There is evidence of an association between malnutrition, inflammation, and atherosclerosis 
(MIA) in ESRD patients, and some researchers have suggested that depression might be 
involved in the MIA syndrome (Simic Ogrizovic et al., 2009). Others have demonstrated 
frequent and close relationships between serum albumin levels and depression (Huang & 
Lee, 2007; Hung et al., 2011; Koo et al., 2003). However, a correlation between hemoglobin, 
ferritin, and emotional symptoms is less clear-cut (Bossola et al., 2009; Czira et al., 2011; 
Huang & Lee, 2007). Hopefully the causal relationships in the complexity of 
psychoneuroimmune mechanisms will be further elucidated in future studies.  
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Racial effects on depression and anxiety have been studied in HD patients, once again with 
conflicting results (Feroze et al., 2010). Higher prevalence rates of major depressive 
disorders have been noted among Caucasians than among African-Americans or Mexican-
Americans (Riolo et al., 2005). In contrast, the results of some studies revealed no differences 
in the prevalence of depression among races (Chen et al., 2011; Weisbord et al., 2007b). 
Balakrishnan et al. (2004) demonstrated that single nucleotide polymorphisms in the 
promoter region of the proinflammatory cytokines appear to have a strong association with 
indices of comorbidity, biological and nutritional markers. Whether depression is associated 
with a genetic predisposition for racial differences or cytokine gene polymorphisms 
warrants further investigation. 
Other studies have evaluated the possible effects of dialysis materials on depression. 
Peritoneal dialysis (PD) patients have been noted to have less severe anxiety, insomnia, and 
depression than do HD patients (Ginieri-Coccossis et al., 2008; Noshad et al., 2009). It has 
been suggested that the rate of depression is greater among patients using cellulose-
derivative dialyzers than among those using polysulfone dialyzers (Hsu et al., 2009). Using 
PD or more biocompatible dialyzers thus might be associated with better mental health in 
HD patients. 
2.3 Psychological and social factors for depression 
A number of studies have focused upon the effects of HD patients, including feelings of 
hopelessness, perceptions of loss and lack of control, job loss, and altered family and social 
relationships (Kimmel, 2001). Because ESRD is a lifelong disease, feelings of lack of control 
and perceptions of overwhelming illness might be inevitable. The intrusiveness of these 
thoughts is related to depression (Christensen & Ehlers, 2002; Devins et al., 1997). 
More recent work has focused upon the possible effects of underlying illness upon 
depressive symptoms among ESRD patients (Guzman & Nicassio, 2003). Perception of loss 
has been regarded as a strong predictor of depression (Chan et al., 2009), which in turn 
predicts mortality (Chilcot et al., 2011). In terms of the risk by demographic characteristics, 
results have been inconsistent (Taskapan et al., 2005). It was reported that depression among 
dialysis patients increased with increasing age and lower educational levels (Keskin & 
Engin, 2011). In some studies, depressive symptoms were more common among women, 
and increased with unemployment and also rose among patients with higher comorbidity of 
physical diseases (Araujo et al., 2011; Chen et al., 2010; Ibrahim & El Salamony, 2008). Thus, 
negative cognition and lack of social support might exacerbate patients’ negative feelings, 
and thus further contribute to depression.  
3. Anxiety 
Anxiety is also commonly seen in HD patients (Kring & Crane, 2009). Cukor et al. 
demonstrated a 27% incidence of anxiety among 70 urban HD patients, which was 
somewhat higher than the 18% incidence reported in a national survey (Kessler et al., 2005). 
During a 16-month follow-up study, 9% of patients had both anxiety and depression at 
baseline; the incidence of both conditions rose to 13% by the end of the study. At the end of 
the study, two-thirds of individuals with comorbid depression and anxiety at baseline had 
both diagnoses (Cukor et al., 2008b). Furthermore, Cukor et al. (2008a) reported that 45.7% 
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of a group of dialysis patients recruited from a single center met criteria for an anxiety 
disorder. The most prevalent disorders were specific phobias (26.6%) and panic disorder 
(21.0%). Bossola et al. (2010) indicated that 47.5% of 80 HD patients had mild symptoms of 
anxiety, while 48.7% had moderate or severe symptoms of anxiety. In addition, the anxiety 
scores correlated significantly with age and comorbidities, and anxiety were commonly 
noted in patients with poor appetite (Bossola et al., 2011). A review of 55 studies that 
investigated symptoms of anxiety in ESRD patients found that 12% to 52% of patients with 
ESRD had substantial anxiety (Murtagh et al., 2007). 
In one of our previous studies, 21% of dialysis patients had symptoms of anxiety. In 
addition, 15.5% of these subjects had comorbid depression and anxiety, and 44.3% of 
depressed patients had comorbid anxiety (Chen et al., 2010). Furthermore, suicide risk was 
not only attributed to depression, but also to anxiety.  
The call for depression screening in HD patients is growing, but screening for anxiety in 
patients with ESRD population is relatively disregarded. This is an indication that many 
clinicians underestimate the importance of anxiety among HD patients. O'Donovan et al. 
(2010) reported that clinically anxious participants exhibited significantly lower levels of 
morning cortisol and significantly higher levels of IL-6, compared with non-anxious 
participants. Uncertainty about the future and fear of losing control of one’s life are 
important factors associated with anxiety that adversely impact emotional stability (Haenel 
et al., 1980).  Notably, anxiety is a common psychological problem that may emerge during 
the initial course of dialysis (Cukor et al., 2008b), and is a reminder to clinicians to pay close 
attention to this issue.  
4. Fatigue 
Fatigue is a subjective symptom characterized by tiredness, weakness, and lack of 
energy.(Lee et al., 1991) Fatigue is also one of the most debilitating symptoms reported by 
HD patients, and roughly 60% to 97% of patients on HD experience some degree of it 
(Jhamb et al., 2008). People with chronic renal disease, regardless of whether they are pre-
dialysis or receiving either HD or PD, are reported having high levels of fatigue and are 
often unable to engage in normal daily activities (Bonner et al., 2010). In addition, fatigue is 
positively correlated with depression (Chen et al., 2010; Sklar et al., 1996), and negatively 
correlated with QoL (Lee et al., 2007). In one study, researchers noted a significant 
relationship between the duration of treatment and the level of fatigue. The experience of 
fatigue was more commonly reported in respondents who had been receiving treatment for 
more than 2 years, compared to those treated for less than 2 years (Letchmi et al., 2011). In a 
longitudinal analysis of 917 incident HD and PD patients, those with lower levels of fatigue 
at baseline survived longer (Jhamb et al., 2009).  
Factors that may contribute to fatigue in dialysis patients include anemia, malnutrition, 
inflammation, depression and/or sleep disorders (Jhamb et al., 2008). Anemia resulting 
from reduced erythropoietin production has been cited as an important cause of fatigue in 
this population (Singh et al., 2006). Additionally, patients undergoing chronic HD show 
evidence of accelerated protein catabolism, which might be due to the significant loss of 
amino acids induced by dialysis (Pertosa et al., 2000). Thus, it is reasonable to presume that 
lower levels of albumin can be significantly correlated with greater levels of fatigue (Bonner 
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et al., 2010). Malnutrition in dialysis patients might also be related to poor intake, or the 
result of chronic inflammation (Stenvinkel et al., 1999). Cytokines productions, particularly 
IL-6, might induce protein catabolism and lipolysis (Memoli et al., 2002), and cytokines have 
a strong negative correlation with serum albumin levels in HD patients (Montinaro et al., 
2010). Thus, chronic inflammation and malnutrition might result in fatigue by either directly 
activating the central nervous system through adrenal axis or by indirectly triggering 
multisystem deregulation (Jhamb et al., 2008).  
5. Decreased Quality of Life (QoL) 
Health-related QoL is an important measure of how a disease affects the lives of patients. 
The QoL domains include physical, psychological, and social functioning and general 
satisfaction with life (Tsay & Healstead, 2002). Once patients with ESRD start to receive HD, 
they must face the chronic stress related to restrictions on their time, the economical and 
vocational costs related to treatment, functional limitations, dietary constraints, and possible 
adverse effects of medications (Son et al., 2009). Numerous studies have demonstrated that 
these patients have a lower QoL than that of healthy populations (Kao et al., 2009; Perlman 
et al., 2005; Wolcott et al., 1988). Depression is strongly correlated with decreased health-
related QoL, especially in mental dimensions (Chen et al., 2010; Kao et al., 2009). 
Furthermore, several studies have shown that patients with poorer QoL had a higher 
incidence of anxiety and fatigue (Kring & Crane, 2009), and longitudinal follow-up showed 
increased mortality (Drayer et al., 2006; Wolcott et al., 1988). 
Biological function, mental illnesses, general health perception, and characteristics of the 
individual and environment may contribute to the variability in patients’ QoL (Kring & 
Crane, 2009). Biological factors that have been associated with QoL include altered 
hemoglobin, albumin, ferritin, CRP, IL-6, IL-8, and TNF-α levels (Farag et al., 2011; Kalender 
et al., 2007a; Montinaro et al., 2010; Perlman et al., 2005). Poor exercise tolerance and muscle 
weakness may limit daily activity, again causing poor QoL (Hsieh et al., 2007; Sakkas et al., 
2003). However, Barros et al. (2011) suggested there was no association of nutritional status 
with malnutrition-inflammation, QoL, or depressive symptoms. There is still debate about 
whether patients’ QoL can be directly correlated to malnutrition-inflammation markers.  
  Among psychological issues, uncertainty about the future and lack of energy emerged as 
the major contributors to poor QoL (Tsay & Healstead, 2002). A patient’s dependency on 
treatment may negatively impact his or her QoL and exacerbate feelings of a loss of control 
(Chilcot et al., 2008). Improved QoL is correlated with higher self-esteem and lower levels of 
mood disturbances (Wolcott et al., 1988). Furthermore, time of diagnosis of chronic renal 
failure may be an important factor related to the QoL of patients receiving dialysis. Late 
diagnosis of renal failure and the consequent lack of predialysis care adversely affect QoL 
among these patients (Sesso & Yoshihiro, 1997). Therefore, early detection of renal failure 
and identification of underlying mental illnesses might be important issues for establishing 
better QoL in HD patients.  
6. Suicide 
Suicide may be the most serious result of mental illness among HD patients. Kurella et al. 
(2005) reported the death rate from suicide was 0.24% per 1000 dialysis patients-years at 
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risk. Patients with ESRD had a significantly higher rate of suicide compared with the 
general population in the United States. Chen et al. (2010) demonstrated that among 200 
patients with HD, 21.5% had suicidal ideation; 3.5% had planned a suicide attempt in prior 
months; and 3.5% had attempted suicide during their lifetime. It is noteworthy that an 
increased number of patients with ESRD had withdrawn from dialysis before their death. 
Nevertheless, only a small proportion (12%) of the respondents were unsure or believed that 
discontinuing dialysis was the equivalent of suicide (Cohen et al., 2002). If the data on 
withdrawal from dialysis were factored into current epidemiologic investigations, the 
suicide rate among HD patients might be much greater.  
Suicide was associated with several demographic characteristics among HD patients. 
Independent predictors of suicide included old age, male gender, lower educational status, 
alcohol or drug dependence, and recent hospitalization for mental illness (Keskin & Engin, 
2011; Kurella et al., 2005). Having strong religious beliefs has been suggested as one 
protective factor of suicide risk among HD patients (Martiny et al., 2011). Preexisting 
depression and anxiety disorders have been identified as independent risk factors for 
subsequent onset of suicidal ideation and attempts in the general population (Martiny et al., 
2011; Sareen et al., 2005). Specific for HD patients, suicide risk was also significantly 
predicted by anxiety and depression. On the other hand, fatigue and QoL may not directly 
affect suicide risk (Chen et al., 2010). Because suicide might be preventable via early 
detection of warning signs, it is crucial to identify the psychological impact and possible risk 
of suicide among dialysis patients. 
7. Managing the psychological impact on dialysis patients 
Numerous studies investigated the managements for mental illness in HD patients, 
including pharmacological and non-pharmacological interventions (Table 2).  
7.1 Pharmacological interventions 
Today, selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice for HD 
patients with depression or anxiety (Raymond et al., 2008). Fluoxetine has been effective and 
safe in HD patients, although trials have thus far involved only small numbers of patients 
(Blumenfield et al., 1997). Citalpram, which is similar to fluoxetine in treatment effects, is 
thought to be safe (Cohen et al., 2004), and it has been beneficial for improving QoL in HD 
patients (Kalender et al., 2007b). Paroxetine, combined with supportive psychotherapy, has 
been shown to be not only successful for treating depression, but also for improving 
nutritional status in chronic HD patients with depression (Koo et al., 2005). Sertraline has 
safe pharmacokinetics in patients with ESRD, and treatment with sertraline in PD patients is 
associated with improved of QoL and fewer symptoms of depression (Atalay et al., 2010). 
Duloxetine and venlafaxine, which are categorized as serotonin-norepinephrine reuptake 
inhibitors, are beneficial for patients with major depressive disorder (Ye et al., 2011). 
However, these agents’ safety and efficacy have not been specifically established for HD 
patients. Bupropion, a dopamine-norepinephrine reuptake inhibitor, and mirtazapine, a 
noradrenergic and specific serotonergic, have also been widely used for patients with 
depression. However, once again, it is not clear whether the beneficial effects of these agents 
can be generalized to dialysis patients. Generally, older tricyclic medications have an 
adverse cardiac profile and anticholinergic effects, which limits their use for HD patients 
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Treatment 
Target 
Symptoms 
Side Effects Clinical Consi
Pharmacological interventions    
Selective serotonin reuptake inhibitors  
(fluoxetine, citalopram, paroxetine, 
sertraline) 
Depression 
Anxiety 
Gastrointestinal symptoms, 
sexual dysfunction, risk of 
bleeding, suicidal ideation  
Fluoxetine: lon
Citalopram: use cautiously in 
severe renal im
patients. 
Paroxetine: u
Serotonin-norepinephrine reuptake 
inhibitors (venlafaxine, duloxetine) 
Depression 
Accumulation of toxic 
metabolites, sexual 
dysfunction, hypertension 
Decrease total
in mild-to-
impairment. 
 Dopamine-norepinephrine reuptake 
inhibitors  
(bupropion)  
Depression 
Fatigue 
Insomnia, agitation, seizure, 
accumulation of toxic 
metabolites  
Use with cauti
reduction 
impairment. 
Noradrenergic and specific 
serotonergics  
(mirtazapine) 
Depression 
Sedation, somnolence, 
weight gain 
Reduce do
Tricyclics and tetracyclics 
(amitriptyline, desipramine,doxepin, 
nortriptyline) 
Depression 
Anticholinergic effects, 
sedation,  
QTc prolongation, cardiac 
arrhythmias, orthostatic 
hypotension 
Avoid if pos
side effects. 
Serotonin modulators 
(netazodone, trazodone) 
Depression 
Accumulation of toxic 
metabolites, liver failure (for 
nefazodone), sedation, 
hypotension, cardiac 
arrhythmias 
Avoid use
cardiac disea
Erythropoietin  
Fatigue 
Quality of life 
Seizures, increased clotting, 
and influenza-like 
syndromes 
No significant 
between once
thrice-weekl
administration.  
w
w
w
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Treatment 
Target 
Symptoms 
Side Effects 
Pharmacological interventions    
Partial Serotonin 5HT(1A) receptor 
agonists 
(buspirone) 
Anxiety 
Dizziness, nausea, headache, 
insomnia, tremor 
Usually 25%
reduction 
Benzodiazepines 
(alprazolam, lorazepam, diazepam, 
midazolam, chlordiazepoxide) 
Anxiety 
Insomnia  
Prolong sedation, physical 
and psychological 
dependence, cognition 
impairment, withdrawal 
symptoms 
High rate of 
Alprazolam an
increased free f
protein bound 
Non-pharmacological interventions    
Cognitive behavior therapy (CBT) 
Depression 
Quality of life 
Takes longer time to reach 
effects than pharmacological 
treatment 
Group therap
need well
Exercise training 
Depression 
Quality of life 
No serious adverse effects 
were reported 
10-month to 1-year exercise 
training progra
the heart rate variability (HRV) 
indice
Acupuncture Quality of life 
No serious adverse effects 
were reported 
In
treatments provided twice a
week for 6 
Social support, marital, family 
counseling 
Depression 
Spousal 
depression 
No serious adverse effects 
were reported. 
Treatment programs need to 
comprehensive. 
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In summary, with the exception of the SSRIs, the efficacy and safety of antidepressant drug 
therapy in dialysis patients have not been clearly established, although these medications 
are believed to improve depression empirically. Notably, the relative activity and mode of 
excretion of metabolites of antidepressants in dialysis patients are as yet unknown and may 
complicate the use of these drugs if adverse events occur. It also remains unclear whether 
there are potential drug-drug interactions between antidepressants and other drugs 
commonly used in HD patients. Therefore, the general rule for prescribing antidepressants 
among HD patients is to start at a lower dose and increase the dosage gradually (Cohen et 
al., 2004). 
There is evidence that the use of erythropoietin-stimulating agents might reduce fatigue and 
improve QoL among ESRD patients (Jones et al., 2004). Benzodiazepines (BZD), such as 
diazepam, alprazolam, and lorazepam, have been successfully used to relieve acute 
episodes of panic and anxiety. In addition, BZD are also widely prescribed for HD patients 
with insomnia (Wyne et al., 2011). In recent years, the use of non-BZD drugs such as 
zolpidem, zopiclone, and zaleplon for insomnia patients has rapidly increased. However, it 
is noteworthy that the liability for abuse and dependence exist in both BZD and non-BZD 
drugs, especially with long-term use (Victorri-Vigneau et al., 2007). Buspirone, a partial 
serotonin agonist that acts on the 5HT(1A) receptor, is often recommended for patients with 
anxiety, and it is generally is considered to have fewer unfavorable side effects than does 
BZD. Generally, it is not necessary to adjust the dosage of most of the erythropoietin-
stimulating agents we have mentioned for the level of the glomerular filtation rate, for these 
agents are metabolized in the liver (Hedayati & Finkelstein, 2009). However, buspirone and 
lorazepam may take longer to be eliminated in ESRD patients, and thus the dosage of these 
two drugs should be carefully titrated. Notably, Winkelmayer et al. (2007) reported that 
BZD or zolpidem are commonly used for incident dialysis patients and may be associated 
with greater mortality in this group. Although the causal reference to this effect warrants 
further investigation, it is also a warning that clinicians need to consider the necessity of 
long-term use of BZD in dialysis patients.  
7.2 Non-pharmacological interventions 
Psychotherapy has been used for a wide range of chronic illnesses, including patients with 
HD (Hedayati & Finkelstein, 2009). Of these approaches, cognitive behavioral therapy 
(CBT), a well-documented evidence-based therapy for depression, has been shown to be 
effective (Chen et al., 2011; Duarte et al., 2009). CBT is based on the assumption that one’s 
dysfunctional “automatic thoughts” in response to a situation can result in strong negative 
feelings/emotions, and thus lead to depression. Correction of those faulty dysfunctional 
constructs can lead to clinical improvement. Duarte et al. (2009) demonstrated that CBT 
performed during 3-month-long group therapy is effective for improving depression and 
many dimensions of QoL in chronic HD patients. Chen et al. (2011) conducted a randomized 
controlled interventional study of 72 sleep-disturbed HD patients. Compared with the 
control group (who received sleep health education), patients who received CBT had 
significant improvements in sleep quality, fatigue, depression, and anxiety. Interestingly, 
CRP, IL-18, and oxidized low-density lipoprotein levels also significantly declined among 
those receiving CBT in comparison to those in the control group (Chen et al., 2011). Thus, 
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these studies suggest that CBT might be effective for improving mental health, and for 
reducing inflammation and oxidative stress in HD patients. 
Exercise programs may have a beneficial effect on depressive symptoms in patients with 
ESRD. Ouzouni et al. (2009) reported that 10-month intradialytic exercise training improved 
QoL in both physical functioning and psychological status in HD patients, and decreased 
in self-reported depression. In another study, a 1-year exercise training program reduced 
emotional distress and concomitantly improved cardiac autonomic modulation measured 
by heart rate variability (HRV) indices (Kouidi et al., 2010). For alternative therapy, Kim et 
al. (2011) reported that 24 HD patients who received individualized acupuncture 
treatments over 6 consecutive weeks showed significant improvements in some QoL 
subscales.  
Social support has been shown to help improve emotional disturbances in a variety of 
chronic illnesses. Support and education, either individually to patients or including their 
caregivers and family members, may be helpful (Symister & Friend, 2003). A patient’s 
depression could be influenced by the psychosocial status of his or her spouse, and the 
spouse might be amenable to interventions that could improve patient outcome (Daneker 
et al., 2001). Social support has been shown to decrease depression by improving the self-
esteem of patients with ESRD, which led to increased optimism (Symister & Friend, 2003). 
Treatment programs that address problems with social interactions of patients need to be 
comprehensive, and should explore use of family and marital counseling, and 
involvement of the community, along with consideration of the patient’s social life (Cohen 
et al., 2007). 
8. Conclusion 
HD is a life-sustaining treatment for patients with ESRD; however, it adversely affects 
patients’ mental status. Increasingly, depression is being recognized as a substantial 
comorbid illness in these patients. Anxiety, feelings of fatigue, and decreasing QoL are also 
significant psychological symptoms, and they may be interrelated. Depression and anxiety 
particularly increase patients’ suicide risk. Mental illnesses may have underlying biological 
and psychological causes. There is considerable evidence that these psychological effects are 
associated with adverse outcomes in HD patients with ESRD. It is important, therefore, to 
develop systematic approaches to screening patients for mental illness, and then planning 
treatment strategies. To improve treatment outcome and patient Qol, a comprehensive 
management plan that includes pharmacological and psychosocial interventions, is 
essential.  
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